UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $6
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $8 to $6.
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $8 to $6.